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Background: Extrathyroidal extension (ETE) is a significant prognostic factor in papillary thyroid carcinoma
(PTC). Minimal extrathyroidal extension (mETE) is characterized by involvement of the sternothyroid muscle
or perithyroid soft tissue, and is generally identified by light microscope examination. Patients with mETE,
identified pathologically, are automatically upstaged to pT3. However, the prognostic implications of mETE
have been a source of controversy in the literature. Moreover, there is also controversy surrounding the
identification of mETE on pathological specimens. The objective of this study was to determine the level of
agreement among expert pathologists in the identification of mETE in PTC cases.
Methods: Eleven expert pathologists from the United States, Italy, and Canada were asked to perform a review
of 69 scanned slides of representative permanent sections of PTC specimens. Each slide was evaluated for the
presence of mETE. The pathologists were also asked to list the criteria they use to identify mETE.
Results: The overall strength of agreement for identifying mETE was slight (j= 0.14). Inter-pathologist
agreement was best for perithyroidal skeletal muscle involvement (j= 0.46, moderate agreement) and worst for
invasion around thick-walled vascular structures (j= 0.02, slight agreement). In addition, there was disagree-
ment over the constellation of histologic features that are diagnostic for mETE, which affected overall
agreement for diagnosing mETE.
Conclusions: Overall agreement for the identification of mETE is poor. Disagreement is a result of both
variation in individual pathologists’ interpretations of specimens and disagreement on the histologic criteria for
mETE. Thus, the utility of mETE in staging and treatment of PTC is brought into question. The lack of
concordance may explain the apparent lack of agreement regarding the prognostic significance of this patho-
logic feature.
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Introduction
Extrathyroidal extension (ETE) has long been citedas an important prognostic factor in the treatment of
papillary thyroid cancer (PTC). The reported incidence of
ETE in the literature varies between 5% and 45% (1). The
following factors have shown to increase the risk of ETE: age
‡50 years, large tumor size (>4 cm), nonencapsulated tumors,
aggressive histologic variants (e.g., tall-cell variant, diffuse
sclerosing variant, hobnail variant), and the presence of nodal
or distant metastasis (1). ETE increases the risk of both re-
currence and mortality in patients with PTC (1–7). As such,
the presence of ETE is used to upstage a patient with well-
differentiated PTC in numerous staging systems (EORTC,
AJCC-TNM, AMES, and MACIS) (8–11).
The seventh edition of the AJCC-TNM staging system for
thyroid carcinomas divides ETE into minimal and significant
ETE (12). Minimal ETE (mETE) is characterized by in-
volvement of the sternothyroid muscle or perithyroid soft
tissue, while significant ETE is characterized by invasion into
subcutaneous soft tissue, larynx, trachea, esophagus, or re-
current laryngeal nerve. Significant ETE is usually appreci-
ated at a macroscopic level in the operating room, whereas
mETE is determined by light microscopic examination.
Significant ETE can also be appreciated on ultrasound when
capsular disruption is observed (13). Currently, mETE up-
stages a carcinoma measuring <4.0 cm to pT3, whereas sig-
nificant ETE upstages a patient to pT4.While significant ETE
remains an important factor in predicting prognosis, recur-
rence, and mortality in thyroid cancer cases, the impact of
mETE on patient outcome is controversial. Several studies
have found that mETE alone does not worsen survival rates in
PTC (14,15). These findings raise the question of whether
patients ought to be upstaged on the basis of mETE alone.
The authors recently reported the strong association be-
tween tumors withmETE and lymph nodemetastases showing
extranodal extension (ENE). These co-occurrences may serve
as an indicator of the biologic behavior of the primary tumor,
which is conferred to the lymph node (16). ENE has been well
documented to affect prognosis poorly (17). The correlation
between mETE and ENE suggests that there is a reason to
identify mETE, and that the presence of mETE should upstage
the primary tumor. The biology of a tumor that displays ENE
and/or mETE may be more aggressive and warrant treatment
that is more vigorous.
There is controversy as to what histologic criteria constitute
mETE. Mete et al. reviewed the anatomy of the neck organs,
including the thyroid gland, and emphasized that the thyroid
gland does not have a defined, limiting fibrous capsule but ra-
ther an incomplete, thin fibroadipose pseudocapsule. As such,
Mete et al. proposed that involvement of adipose or fibrous
tissue does not necessarily indicate ETE of the tumor (18).
Furthermore, though skeletal muscle invasion does represent
extrathyroidal spread, this is only reliable in the lateral lobes of
the thyroid, and may not be reliable in the isthmus, since fibers
ofSoemmerring’smuscle (a small strapmuscle arising from the
hyoid bone and inserting partly on the thyroid cartilage and
partly on the isthmus, also known as musculus levator glan-
dulae thyroidae of Soemmerring) can be identified in this par-
ticular location (18). Further, mesenchymal tissues normally
located outside the thyroid gland, including fibrous and adipose
tissue, nerve, muscle, and thick-walled blood vessels, can be
found within the substance of the thyroid gland. Such findings
may complicate the evaluation of mETE, making the actual
pathologic diagnosis ofmETE subjective and problematic (18).
Controversy surrounding the prognostic significance of
mETE may be related to disagreement among pathologists
about the definition of mETE and discordance in its identifi-
cation. To the authors’ knowledge, there are no reported studies
assessing the degree of concordance among pathologists in
the assessment of mETE. This study evaluates inter-observer
variation in the histologic identification of mETE. The im-
portance of this analysis is designed to alert clinicians to any
variability that may exist and also to determine whether a lack
of concordance may be a root cause for the controversy re-
garding the prognostic significance of this histologic feature.
Methods
Institutional Review Board approval was obtained at
Mount Sinai Beth Israel for this retrospective review. Eleven
expert pathologists from the United States, Italy, and Canada
were asked to perform a review of 69 scanned slides of rep-
resentative permanent sections of PTC specimens from the
Mount Sinai Beth Israel Medical Center in New York. Cases
were selected on the basis of availability in the department at
the time the study was undertaken. One slide was chosen
because of limitations of digital scanning available from a
non-departmental (commercial) vendor. The best slide in a
given case was chosen for scanning. Before scanning, slides
were selected specifically for being potentially controversial
with respect to the presence of mETE, as determined by the
lead pathologist (B.M.W.). All slides were prepared with
hematoxylin and eosin stain in accordance with standard
procedures at the Mount Sinai Beth Israel Medical Center.
The slides were digitally scanned at 40· using the Aperio
ScanScope AT Turbo. All 11 pathologists evaluated all cases.
Pathologists reviewed each slide and designated it as
demonstrating mETE or having no evidence of mETE, spe-
cifically evaluating the specimen for perithyroidal involve-
ment of fat, skeletal muscle, nerves, and thick-walled
vascular structures. Involvement of thick-walled vascular
structures included growth of tumor cells/nests around and
beyond thick-walled vascular blood vessels located at the
periphery of the sections. As involvement of the recurrent
laryngeal nerve would be quantified as significant ETE, pa-
thologists were aware in advance that any nerve involvement
did not include the recurrent laryngeal nerve. The specific
criteria used by each pathologist for diagnosing mETE were
recorded. Each pathologist was also asked to explain if he or
she used different criteria to classify mETE for a primary
cancer arising from the isthmus. The pathologists involved in
the study were informed that this study would be to evaluate
digitally scanned slides in cases of PTC for the presence or
absence of minimal mETE in order to evaluate the concor-
dance or lack thereof among expert thyroid pathologists.
The kappa coefficient was computed to assess consistency
in the pathologists’ categorization of each slide and the cri-
teria used. All statistical analyses were done with R statistical
package v3.1.1.
Results
The kappa coefficient for the presence of mETE was 0.14,
suggesting that the overall strength of agreement in identifying
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mETE was slight (Table 1). Inter-pathologist agreement was
best for perithyroidal skeletal muscle involvement (j= 0.46,
moderate agreement) and worst for involvement of thick wal-
led vascular structures (j= 0.02, slight agreement).
Seven out of 11 pathologists reported using perithyroidal
fat, skeletal muscle, nerve, and thick-walled vessel (Fig. 1)
involvement as histologic criteria for diagnosing mETE
(Table 2). Two pathologists reported using all of these criteria
except perithyroidal thick-walled vessel involvement for
reporting mETE, and two pathologists reported using only
perithyroidal skeletal muscle involvement for identifying
mETE. Five pathologists also reported using desmoplasia as
a criterion for diagnosing mETE. Additional criteria noted
include ‘‘lack of fat’’ surrounding the tumor and ‘‘extrinsic
extension into vessels, not tumor emboli.’’
The data were analyzed with data removed from two pa-
thologist raters who only considered perithyroidal skeletal
muscle involvement as evidence of mETE (pathologists 6
and 9; Table 2) because their criteria for mETE were quite
different compared with the other nine pathologists. When
the data from pathologists 6 and 9 were removed from the
sampling, the kappa values increased slightly (Table 3). The
kappa coefficient for the overall presence of mETE increased
from 0.14 to 0.23. Kappa values also increased slightly for
perithyroidal fat and thick-walled vessel involvement.
However, kappa values decreased slightly for perithyroidal
nerve and skeletal muscle involvement. While there was a
small increase in kappa for some values, this was not statis-
tically significant.
Criteria used for diagnosing mETE in primary tumors
arising from the isthmus of the thyroid varied as well. Five
pathologists stated they do not use different criteria to diag-
nose mETE in the isthmus, while six reported that they use
more stringent criteria. Of these six, four reported that they
consider skeletal muscle invasion near the isthmus to be less
important, and two reported that adipose tissue involvement
near the isthmus is less important.
Discussion
The pathologic diagnosis of mETE is subjective, without
clearly established histopathologic diagnostic criteria, and
the overall inter-pathologist concordance among 11 expert
pathologists was poor. There was variation in individual
pathologists’ interpretations of the presence of mETE, as well
FIG. 1. Papillary thyroid
carcinoma with (A) involve-
ment of perithyroidal fat
(hematoxylin and eosin
[H&E]; 40·); (B) perineural
invasion (arrowheads)—note
the thick-walled blood vessel
to the extreme right (H&E;
20·); (C) invasion into and
beyond skeletal muscle
(H&E; 10·); and (D) exten-
sion around perithyroidal
thick-walled blood vessels
(arrows) (H&E; 10·).
Table 1. Kappa Coefficient for Inter-Pathologist
Agreement of Presence of mETE and Involvement
of Perithyroidal Structures
Criteria for mETE
Kappa
coefficient
Strength of
agreementa
Proportion
of observed
agreement
Presence of mETE 0.14 Slight 0.59
Perithyroidal fat
involvement
0.16 Slight 0.58
Perithyroidal nerve
involvement
0.11 Slight 0.88
Perithyroidal
skeletal muscle
involvement
0.46 Moderate 0.91
Perithyroidal
thick-walled
vessel
involvement
0.02 Slight 0.67
aKappa agreement: <0, less than chance agreement; 0.00–0.20,
slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate
agreement; 0.61–0.80, substantial agreement; 0.81–0.99, almost
perfect agreement.
mETE, minimal extrathyroidal extension.
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as whether individual tissues (fat, muscle, nerve and thick-
walled vessel) were affected. Additionally, there was dis-
agreement in the criteria used by individual pathologists to
identify mETE. When the findings of two pathologists with
very different definitions of mETE (pathologists 6 and 9)
were removed from the statistical analysis, kappa coefficients
did not change significantly.
Controversy as towhat histologic findings constitutemETE
appears to stem partially from disagreement over whether
perithyroidal invasion of fat and nerves around or beyond
thick-walled vascular structures constitutes evidence for
mETE (18). Since thyroid tissue may be present as a normal
histologic variantwithin perithyroidal fat and skeletalmuscle,
and, alternatively, fat and muscle may be found within the
thyroid (especially at the periphery of the gland, including the
isthmus), identifying involvement of these types of tissue does
not necessarily indicate the extrathyroidal extent of the tumor
(18). One pathologist specified that only extrinsic extension
into blood vessels, rather than tumor emboli, would constitute
mETE.
The kappa coefficients were low for the identification of all
features and for the determination of mETE, even when
outlier pathologists were removed from the analysis. How-
ever, these kappa values are affected by the low number of
events in the data (i.e., positive identification of mETE). In
other words, raters overall identified involvement of peri-
thyroidal structures and mETE rarely in the 69 slides studied.
Therefore, it is important to place the kappa values in the
context of the proportion of agreement. The proportion of
agreement was >0.50 for all values, indicating that the kappa
coefficients would have been higher had there been a more
representative sample, with more cases of mETE.
The proportion of agreement was high for perithyroidal
nerve and skeletal muscle involvement (0.88 and 0.91, re-
spectively) compared with the proportion of agreement for
the presence of mETE overall (0.59). This finding suggests
that a part of the disagreement between pathologists on the
presence of mETE lies not in the identification of tumor in-
vasion in various perithyroidal tissues, but in the decision to
interpret a constellation of such histologic features as diag-
nostic for mETE. Therefore, clear delineation of the histo-
logic criteria for mETE may have an important role to play in
improving uniformity in the diagnosis of mETE. However,
based on low kappa coefficients and only moderate propor-
tions of agreement for the identification of perithyroidal fat
and thick-walled vessel involvement, there appears to be
disagreement in identifying these features, which also con-
tributes to the low kappa coefficient for the overall presence
of mETE. Further evaluation of this finding is warranted with
a larger sample. Additionally, a study is warranted that would
examine the prognostic implications of these variations in the
determination of mETE.
There are several potential limitations of this study. First,
the sample size included only 11 pathologists. Second, senior
pathologists were utilized from various medical centers in the
United States, Canada, and Italy who are considered experts
in thyroid pathology. This naturally biases the group toward
pathologists who are more experienced with mETE and PTC.
This group is not necessarily representative of all pathologists
who review thyroid specimens less frequently. It is possible
that the degree of concordance for diagnosing mETE would
be lower for all pathologists than for pathologists with ex-
tensive expertise in this area. However, given the low kappa
values for even these senior pathologists, it is unclear if this
would be the case. A second study designed to engage pa-
thologists in community hospitals would help elucidate this
point. A third limitation is that the pathologists were only sent
one representative slide from each specimen. In practice,
pathologists often review multiple slides and have the ability
to probe further should a particular diagnosis be in question.
A fourth limitation is that the 69 cases used in this study were
selected because they were determined to be potentially
controversial for the presence of mETE by the senior pa-
thologist; this could have influenced the kappa values and
resulted in lower agreement than in non-controversial cases.
Moreover, since the 11 pathologists knew the cases were
being selected for their complexity and ambiguity, this could
have biased their interpretation. A fifth limitation is that the
pathologists could have been affected by the knowledge that
they were graded based on their interpretation.
mETE is a controversial prognostic factor in PTC. From
this study, it is apparent that inter-observer concordance for
the identification of mETE between expert pathologists is
moderate to poor. Hence, thyroid cancer patients may be
incorrectly identified as having mETE, or mETE may be
missed in some patients. Recognition of this variation in
pathologic interpretation is important for clinicians to un-
derstand when making clinical decisions regarding their
patients and when reviewing the literature related to this
feature. The results of this study support the need for
standardization of histopathologic criteria for mETE to
achieve more consistency among pathologists from differ-
ent institutions.
Conclusions
This study evaluated inter-observer concordance in the
histologic identification of mETE and proves that the overall
agreement for the identification of mETE is poor. Disagree-
ment is a result of both variation in individual pathologists’
Table 3. Kappa Coefficient for Inter-Pathologist
Agreement of Presence of mETE and Involvement
of Perithyroidal Structures, Nine Raters
Criteria for mETE
Kappa
coefficient
Strength of
agreementa
Proportion
of observed
agreement
Presence of mETE 0.23 Fair 0.69
Perithyroidal fat
involvement
0.20 Slight/fair 0.61
Perithyroidal nerve
involvement
0.10 Slight 0.86
Perithyroidal
skeletal muscle
involvement
0.41 Moderate 0.90
Perithyroidal
thick-walled
vessel
involvement
0.03 Slight 0.63
aKappa agreement: <0, less than chance agreement; 0.00–0.20,
slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate
agreement; 0.61–0.80, substantial agreement; 0.81–0.99, almost
perfect agreement.
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interpretations and disagreement on the histologic criteria for
mETE. Thus, the reliability of pathologists to be consistent in
their interpretation and definition of mETE in PTC is ques-
tioned. Moreover, given the strong association between
mETE and ENE, correct identification of mETE has prog-
nostic implications. Clinicians must be aware of this inherent
variability in reporting mETE. This may confound the in-
terpretation of outcomes studies, which heavily rely upon the
uniform reporting of pathologic features, and this impacts the
staging of thyroid cancer patients.
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